Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic

Simple item page
dc.contributor.authorLeonardo M. R. Ferreira
dc.contributor.authorMohammed A. Mostajo-Radji
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T20:47:11Z
dc.date.available2026-03-22T20:47:11Z
dc.date.issued2020
dc.description.abstractConvalescent plasma therapy holds promise as a transient treatment for COVID-19. Yet, blood products are important sources of HIV infection in low- and middle-income nations. Great care must be taken to prevent plasma therapy from fueling HIV epidemics in the developing world.
dc.identifier.doi10.31235/osf.io/cyqx8
dc.identifier.urihttps://doi.org/10.31235/osf.io/cyqx8
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/84058
dc.language.isoen
dc.sourceNew America
dc.subjectCoronavirus disease 2019 (COVID-19)
dc.subjectLow and middle income countries
dc.subjectHuman immunodeficiency virus (HIV)
dc.subjectMedicine
dc.subjectVirology
dc.subject2019-20 coronavirus outbreak
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
dc.subjectPandemic
dc.subjectLow income
dc.subjectDeveloping country
dc.titlePlasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic
dc.typepreprint

Files

Collections

Artículo Científico (Preprint)